STOCK TITAN

Amylyx Pharmaceuticals (AMLX) Financials

AMLX NASDAQ
FY2025 annual
Revenue $0 -100.0% YoY
Net Income -$144.7M n/m YoY
EPS (Diluted) -$1.53 n/m YoY
Free Cash Flow -$123.5M n/m YoY
Market Cap $3.4B as of Nov 18, 2026
Price / Sales n/m revenue is not positive, FY2025
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 4.5x on $753.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMLX SEC filings page.

Amylyx Pharmaceuticals, Inc. (AMLX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AMLX FY2025

Amylyx's numbers show a high-margin, low-capital model whose economics depend on restoring revenue after FY2024's sharp contraction.

In FY2023, $49.3M of net income became only $11.9M of operating cash flow, with conversion at 24.2%; reported profitability already overstated cash generation. By FY2024, operating cash flow was -$167.6M against a net loss of $301.7M, showing the downturn involved substantial cash consumption rather than merely accounting charges.

Gross margin barely moved from 93.3% to 93.2% while revenue fell 77.1%, separating the earnings collapse from product-level gross economics. Operating margin swung from 10.2% to -360.2% even as operating spending declined, showing the remaining cost structure could not be absorbed by the smaller revenue base.

FY2024 liabilities were only 14.9% of assets and the current ratio was 6.7x, so the reported strain was operating cash generation rather than near-term balance-sheet leverage. Free cash flow nearly matched operating cash flow because capital expenditures were just 0.2% of revenue, indicating cash pressure came from operations rather than heavy reinvestment.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Amylyx Pharmaceuticals, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Safe
71.38

Amylyx Pharmaceuticals, Inc. scores 71.38, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $3.4B against total liabilities of $27.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/7

Amylyx Pharmaceuticals, Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Amylyx Pharmaceuticals, Inc. reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$49.6M
YoYn/m
QoQn/m

Amylyx Pharmaceuticals, Inc.'s EBITDA was -$49.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$45.5M
YoYn/m
QoQn/m

Amylyx Pharmaceuticals, Inc. reported a net loss of $45.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.38
YoYn/m
QoQn/m

Amylyx Pharmaceuticals, Inc. earned -$0.38 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$33.7M
YoYn/m

Amylyx Pharmaceuticals, Inc. recorded an outflow of $33.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Cash & Debt
$240.1M
YoY+6.6%
QoQ+386.8%

Amylyx Pharmaceuticals, Inc. held $240.1M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
129M
YoY+17.1%
QoQ+15.4%

Amylyx Pharmaceuticals, Inc. had 129M shares outstanding in Q3 2026. This represents an increase of 17.1% from the same quarter a year earlier. Against the prior quarter it is up 15.4%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-6.0%
YoY+4.3pp
QoQ+12.1pp

Amylyx Pharmaceuticals, Inc.'s quarterly ROE was -6.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 4.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.1 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$28.4M
YoY+42.8%
QoQ+19.3%

Amylyx Pharmaceuticals, Inc. invested $28.4M in research and development in Q3 2026. This represents an increase of 42.8% from the same quarter a year earlier. Against the prior quarter it is up 19.3%.

Capital Expenditures
$25K
YoY+4.2%

Amylyx Pharmaceuticals, Inc. invested $25K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 4.2% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2026.

AMLX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMLX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
RevenueN/AN/AN/A$0$0-100.0%$0$0-100.0%N/A
Cost of RevenueN/AN/AN/AN/A$0n/m$0-100.0%$0-100.0%N/A
Gross ProfitN/AN/AN/AN/A$0-100.0%$0n/m$0-100.0%N/A
R&D Expenses$28.4M+42.8%$23.8M-12.7%$27.6M+24.8%$21.2M$19.9M-6.5%$27.2M+16.6%$22.1M-39.6%N/A
SG&A Expenses$21.3M+31.8%$21.9M+40.2%$16.2M+3.1%$15.4M$16.2M-9.3%$15.6M-27.7%$15.7M-72.8%N/A
Operating Income-$49.7Mn/m-$45.7Mn/m-$43.8Mn/m-$36.6M-$36.0Mn/m-$42.9Mn/m-$37.8Mn/mN/A
EBITDA-$49.6Mn/m-$45.6Mn/m-$43.7Mn/mN/A-$35.9Mn/m-$42.7Mn/m-$37.6Mn/mN/A
Income TaxN/AN/AN/A$46K$0n/m$0n/m$0-100.0%N/A
Net Income-$45.5Mn/m-$43.4Mn/m-$41.3Mn/m-$33.0M-$34.4Mn/m-$41.4Mn/m-$35.9Mn/mN/A
EPS (Basic)-$0.38n/m-$0.39n/m-$0.37n/m-$0.28n/m-$0.37n/m-$0.46n/m-$0.42n/m-$0.54-871.4%
EPS (Diluted)-$0.38n/m-$0.39n/m-$0.37n/m-$0.28n/m-$0.37n/m-$0.46n/m-$0.42n/m-$0.54-871.4%
Diluted Shares (Avg)119M+27.4%111M+24.7%111M+29.0%N/A93M+37.1%89M+31.0%86M+26.3%N/A

Not reported in any period shown, so not listed: Interest Expense.

AMLX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMLX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$786.8M+116.9%$264.6M+36.0%$293.6M+33.7%$332.6M+71.8%$362.7M+44.7%$194.6M-41.4%$219.7M-47.4%$193.6M-62.6%
Current Assets$778.9M+120.4%$256.3M+37.2%$285.0M+31.9%$323.7M+70.9%$353.4M+44.1%$186.9M-42.8%$216.1M-47.4%$189.4M-59.2%
Cash & Equivalents$240.1M+6.6%$49.3M-15.1%$229.1M+283.4%$226.7M+192.9%$225.2M+213.4%$58.1M-22.6%$59.8M-65.0%$77.4M-54.5%
Short-Term Investments$528.0M+344.4%$201.4M+64.1%$50.6M-64.9%$90.3M-8.9%$118.8M-26.9%$122.7M-47.7%$144.3M-28.8%$99.1M-50.7%
InventoryN/AN/AN/AN/AN/AN/AN/A$0-100.0%
Accounts ReceivableN/AN/AN/A$88K-80.3%$132K-92.4%$103K-97.5%$300K-98.5%$447K-98.9%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$33.1M+7.5%$25.4M-5.0%$20.4M+12.0%$27.4M-5.1%$30.7M-43.6%$26.7M-62.3%$18.3M-80.4%$28.9M-65.6%
Current Liabilities$29.0M+12.6%$21.1M-1.3%$16.0M-11.0%$22.7M-20.1%$25.8M-52.2%$21.4M-69.4%$17.9M-80.4%$28.4M-65.4%
Non-Current Liabilities$4.0M-19.0%$4.2M-19.8%$4.5M+1268.8%$4.7M+914.7%$5.0M+732.6%$5.3M+586.1%$327K-76.3%$463K-76.6%
Total Equity$753.7M+127.0%$239.2M+42.5%$273.2M+35.6%$305.3M+85.3%$332.0M+69.2%$167.9M-35.8%$201.4M-37.9%$164.8M-62.0%
Retained Earnings-$881.6Mn/m-$836.1Mn/m-$792.7Mn/m-$751.4Mn/m-$718.4Mn/m-$684.0Mn/m-$642.6Mn/m-$606.7Mn/m

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

AMLX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMLX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$33.7Mn/m-$31.4Mn/m-$36.9Mn/m-$27.9Mn/m-$30.4Mn/m-$25.2Mn/m-$39.8Mn/m-$59.0M-535.5%
Depreciation & Amortization$33K-72.5%$43K-69.5%$98K-37.2%$108K-32.5%$120K-45.7%$141K-32.2%$156K-50.5%$160K-46.8%
Stock-Based Compensation$10.4M+46.6%$8.3M+13.2%$6.1M-10.4%N/A$7.1M+4.0%$7.3M-23.2%$6.8M-31.1%N/A
Capital Expenditures$25K+4.2%N/AN/A$86K+330.0%$24K$17K-80.9%$11K-83.6%$20K-94.4%
Free Cash Flow-$33.7Mn/mN/AN/A-$28.0M-$30.4M-$25.3Mn/m-$39.8Mn/mN/A
Investing Cash Flow-$325.7M-6319.7%-$149.8M-751.5%$36.3Mn/m$29.5M-54.7%$5.2M-86.5%$23.0Mn/m-$43.7M-5430.8%$65.0M+210.5%
Financing Cash Flow$550.2M+187.1%$1.5Mn/m$3.2M-95.1%-$208K-289.1%$191.6M+239407.5%-$31K-214.8%$65.7M+50023.7%$110K-52.2%
Dividends Paid$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0

Not reported in any period shown, so not listed: Share Buybacks.

AMLX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AMLX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-6.0%+4.3pp-18.2%+6.5pp-15.1%+2.7pp-10.8%-10.4%+26.7pp-24.7%+3.1pp-17.8%+18.8ppN/A
Return on Assets-5.8%+3.7pp-16.4%+4.9pp-14.1%+2.3pp-9.9%-9.5%+19.5pp-21.3%+0.6pp-16.4%+12.1ppN/A
Current Ratio26.81+13.1x12.12+3.4x17.85+5.8x14.27+7.6x13.70+9.2x8.72+4.1x12.05+7.6x6.67+1.0x
Liabilities-to-Equity0.040.0x0.11-0.1x0.070.0x0.09-0.1x0.09-0.2x0.16-0.1x0.09-0.2x0.180.0x
Asset TurnoverN/AN/AN/A0.000.000.0x0.000.0x0.00-0.2xN/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Amylyx Pharmaceuticals, Inc. AMLX FY2025 $0 -$144.7M N/A $3.4B —
Liquidia Corporation LQDA FY2025 $158.3M -$68.9M -43.5% $5.1B 64/100
Xeris Biopharma Holdings, Inc. XERS FY2025 $291.8M $554K 0.2% $3.1B 45/100
Hims & Hers Health, Inc. HIMS FY2025 $2.3B $128.4M 5.5% $4.0B 49/100
Bausch Health Companies Inc BHC FY2025 $10.3B $157.0M 1.5% $3.3B 50/100
HUTCHMED (China) Limited HCM FY2025 $548.5M $456.9M 83.3% $2.4B 42/100

Frequently Asked Questions

Amylyx Pharmaceuticals, Inc. (AMLX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Amylyx Pharmaceuticals, Inc. (AMLX) revenue declined by 100.0% year-over-year, from $87.4M to $0 in fiscal year 2025.

No, Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $144.7M in fiscal year 2025.

Amylyx Pharmaceuticals, Inc. (AMLX) reported diluted earnings per share of -$1.53 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Amylyx Pharmaceuticals, Inc. (AMLX) had EBITDA of -$152.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity of -47.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Amylyx Pharmaceuticals, Inc. (AMLX) recorded an outflow of $123.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Amylyx Pharmaceuticals, Inc. (AMLX) recorded an outflow of $123.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Amylyx Pharmaceuticals, Inc. (AMLX) had $332.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Amylyx Pharmaceuticals, Inc. (AMLX) invested $138K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Amylyx Pharmaceuticals, Inc. (AMLX) invested $90.4M in research and development during fiscal year 2025.

Amylyx Pharmaceuticals, Inc. (AMLX) had 111M shares outstanding as of fiscal year 2025.

Amylyx Pharmaceuticals, Inc. (AMLX) had a current ratio of 14.27 as of fiscal year 2025, which is generally considered healthy.

Amylyx Pharmaceuticals, Inc. (AMLX) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Amylyx Pharmaceuticals, Inc. (AMLX) had a return on assets of -43.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Amylyx Pharmaceuticals, Inc. (AMLX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $3.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Amylyx Pharmaceuticals, Inc. (AMLX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $3.4B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Amylyx Pharmaceuticals, Inc. (AMLX) held $317.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $123.3M over that year. Dividing the one by the other, the reported balance equals about 31 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Amylyx Pharmaceuticals, Inc. (AMLX) has an Altman Z-Score of 71.38, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Amylyx Pharmaceuticals, Inc. (AMLX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $144.7M while operations used $123.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top